
    
      We administered three cycles FOLFOX4 plus TAC(oxaliplatin,FUDR and MMC) or FOLFOX4 plus
      TACE(oxaliplatin,FUDR,MMC and embolision) to primary colorectal tumor resected patients with
      unresected liver metastasis. The study endpoints were resection rate of liver metastasis,
      progression-free survival, overall survival as evaluated by intent-to-treat analysis.
    
  